MP76-20 CLINICAL STAGE I PURE TESTICULAR TERATOMA IN ADULTS: PATTERNS OF CARE AND SURVIVAL OUTCOMES BY TREATMENT STRATEGY

Abstract

You have accessJournal of UrologyPenile & Testicular Cancer: Penile & Testicular Cancer III (MP76)1 Apr 2020MP76-20 CLINICAL STAGE I PURE TESTICULAR TERATOMA IN ADULTS: PATTERNS OF CARE AND SURVIVAL OUTCOMES BY TREATMENT STRATEGY Ali Hajiran*, Mounsif Azizi, Logan Zemp, Ahmet Aydin, Salim Cheryian, Brandon Manley, Scott Gilbert, and Wade Sexton Ali Hajiran*Ali Hajiran* More articles by this author , Mounsif AziziMounsif Azizi More articles by this author , Logan ZempLogan Zemp More articles by this author , Ahmet AydinAhmet Aydin More articles by this author , Salim CheryianSalim Cheryian More articles by this author , Brandon ManleyBrandon Manley More articles by this author , Scott GilbertScott Gilbert More articles by this author , and Wade SextonWade Sexton More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000962.020AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Pure testicular teratoma accounts for less than 5% of testicular neoplasms in adults and is considered less aggressive and less likely to metastasize than other non-seminomatous germ cell tumors (NSGCT). The current literature regarding clinical stage (CS) I pure teratoma is sparse with only a few non-contemporary case series. Following radical orchiectomy, active surveillance (AS) and retroperitoneal lymph node dissection (RPLND) are acceptable management options; however, there is no uniform consensus. The purpose of this study was to investigate the outcomes of patients with CS I pure testicular teratoma based on management strategy. METHODS: Data was extracted from the National Cancer Data Base (NCDB) from testicular cancer patients with CS I (pT1-4N0M0S0) pure teratoma from 2004-2014. Kaplan-Meier curves and Cox regression analyses were used to assess the overall survival (OS) of patients who were managed with AS vs. primary RPLND. RESULTS: Of the 61,167 patients diagnosed with testicular cancer, 692 (1.1%) had pure teratoma. Only individuals with CS I disease were considered (n = 237). The median age was 28 (23-35) years. Overall, 43 (18%) patients underwent RPLND and 194 (82%) patients were managed with AS. There was an increase in AS for CS I teratoma from 2004 to 2014. Increasing distance from residence to treatment facility was an unadjusted predictor for undergoing primary RPLND (OR 7.26, CI 2.84-18.55, p <0.001). Median follow-up was 54 months and there was no significant difference in OS between patients managed with AS vs. RPLND (p = 0.13). CONCLUSIONS: Adults with early stage pure testicular teratoma have excellent outcomes regardless of management strategy. The majority of patients are managed with AS while primary RPLND rates have declined in recent years. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1160-e1161 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ali Hajiran* More articles by this author Mounsif Azizi More articles by this author Logan Zemp More articles by this author Ahmet Aydin More articles by this author Salim Cheryian More articles by this author Brandon Manley More articles by this author Scott Gilbert More articles by this author Wade Sexton More articles by this author Expand All Advertisement PDF downloadLoading ...